POSILAC^® bovine somatotropin is widely accepted and used as a management tool to enhance dairy cow productivity.   Of the nearly 9 million dairy cows in the United States, approximately one-third are in herds supplemented with POSILAC.

Approximately 8,000 dairy producers are currently taking advantage of the benefits offered by POSILAC. The product is sold in all 50 states. Dairy producers using POSILAC have herds ranging in size from 5 to thousands of cows.

Since introduction in February 1994, POSILAC has become the largest selling dairy animal pharmaceutical product in the United States.

To help meet growing world demand for POSILAC, Monsanto has received FDA approval of a new multi-million dollar manufacturing facility in Augusta, Georgia.

The average dairy operator using POSILAC is supplementing more than 50 percent of the herd at any one time.   Customer usage rates on their herds vary depending on individual herd management

Dairy farmers continue to report excellent results with POSILAC -- over 99 percent of producers using POSILAC reported increases in milk production.

Satisfied customers across the United States, many with over twelve years experience, attest to the product's efficacy and safety in dairy herds.   Furthermore, the FDA has confirmed and reconfirmed that POSILAC is safe for cows and does not compromise the safety of the milk supply.

POSILAC continues to prove itself to be an effective management tool that helps dairy producers, both large and small, improve their operations, lower their cost for producing high quality milk and achieve higher profitability.

As an added means of supporting dairy producers, Monsanto works with the feed and animal health industries to help dairy producers improve animal nutrition and herd management practices.

Monsanto is committed to working with producers who experience dairy herd management problems, or who have other concerns, to ensure their experience with POSILAC is successful.